Jonathan Riess, MD, MS

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Bayer
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    06/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Turning Point
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    02/23/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Daiichi Sankyo
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    02/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Beigene
    Topic:
    Advisory Board
    Date added:
    10/15/2022
    Date updated:
    04/23/2024
    Relationship end date:
    03/01/2022

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond